Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry

Endocrine Journal

Volumn 61, Issue 12, 2014, Pages 1171-1180

  Yoshinaga, Keiichiro ^a   Oriuchi, Noboru ^b   Wakabayashi, Hiroshi ^c   Tomiyama, Yuuki ^a   Jinguji, Megumi ^d   Higuchi, Tetsuya ^b   Kayano, Daiki ^c   Fukuoka, Makoto ^c   Inaki, Anri ^c   Toratani, Ayane ^c   Okamoto, Shozo ^a   Shiga, Tohru ^a   Ito, Yoichi M ^a   Nakajo, Masatoyo ^d   Nakajo, Masayuki ^d   Kinuya, Seigo ^c  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

131I MIBG; Malignant paraganglioma; Malignant pheochromocytoma; Neuroendocrine tumor; Radiotherapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; (3 IODOBENZYL)GUANIDINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERTENSION; LEUKOPENIA; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIATION SAFETY; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADRENAL GLAND; ADRENAL GLAND NEOPLASMS; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; DIAGNOSTIC USE; DISEASE COURSE; JAPAN; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RADIATION RESPONSE; REGISTER; SCINTISCANNING; SECRETION (PROCESS); UNIVERSITY HOSPITAL;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ADULT; AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION; IODINE RADIOISOTOPES; JAPAN; MALE; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; REGISTRIES;

EID: 84919789475     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ14-0211     Document Type: Article

References (32)

1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366: 665-675.
2. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, et al. (2014) Pathologic grading for predicting metastasis in phaechromocytoma and paragnglioma. Endocr Relat Cancer 21: 405-414.
3. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134: 315-329.
4. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106-2120.
5. Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, et al. (2013) Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 4: 103-110.
6. Jackson MR, Falzone N, Vallis KA (2013) Advances in anticancer radiopharmaceuticals. Clin Oncol (R Coll Radiol) 25: 604-609.
7. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, et al. (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35: 1941-1959.
8. 131I-MIBG for internal radiotherapy of neuroendocrine tumors. Kaku Igaku 45: supple 1-40 (In Japanese).
9. 131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20: 648-658.
10. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, et al. (2007) Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25: 1054-1060.
11. Nwosu AC, Jones L, Vora J, Poston GJ, Vinjamuri S, et al. (2008) Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 98: 1053-1058.
12. Wakabayashi H, Taki J, Inaki A, Nakamura A, Kayano D, et al. (2013) Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma. Ann Nucl Med 27: 839-846.
13. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, et al. (2009) Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 27: 4162-4168.
14. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, et al. (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-metaiodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 55: 47-60.
15. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, et al. (2003) Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956- 962; discussion 962-963.
16. 131I-MIBG) therapy. Eur J Nucl Med Mol Imaging 35: 1039-1047.
17. Kayano D, Taki J, Fukuoka M, Wakabayashi H, Inaki A, et al. (2011) Low-dose (123) I-metaiodobenzylguanidine diagnostic scan is inferior to (131)I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma. Nucl Med Commun 32: 941-946.
18. Inoue T, Yoshinaga K, Morita K, Shiga T, Kanegae K, et al. (2007) Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy. Ann Nucl Med 21: 307-310.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572.
20. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, et al. (2014) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 37: 253-387.
21. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, et al. (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11: 423-436.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205- 216.
23. 131I-MIBG for advanced metastatic carcinoid tumors. J Nucl Med 54: 2032-2038.
24. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP (2014) (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 80: 487-501.
25. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35: 725-733.
26. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H (2007) Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92: 1217-1225.
27. Grünwald F, Ezziddin S (2010) 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 40: 153-163.
28. Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, et al. (2008) Pheochromocytoma: current approaches and future directions. Oncologist 13: 779-793.
29. Chatal JF, Hoefnagel CA (1999) Radionuclide therapy. Lancet 354: 931-935.
30. Akashi YJ, Goldstein DS, Barbaro G, Ueyama T (2008) Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation 118: 2754-2762.
31. Yoshinaga K, Torii H, Tahara M (1998) A serial echocardiographic observation of acute heart injury associated with pheochromocytoma crisis. Int J Cardiol 66: 199-202.
32. Young WF Jr (2010) Endocrine hypertension: then and now. Endocr Pract 16: 888-902.